GenSight Biologics KOL Event New York 2019

New York, May 23, 2019

Please join key opinion leaders in ophthalmology and the GenSight CEO & CMO for a breakfast and presentation of data from the Phase 3 RESCUE and REVERSE studies of GS010, the gene therapy candidate for the treatment of Leber Hereditary Optic Neuropathy 

Featured Speakers:

Sean Donahue, MD PhD
Coleman Professor of Ophthalmology, Neurology and Pediatrics
Vice Chair of Clinical Affairs, Ophthalmology Vanderbilt University Medical Center, Nashville TN

José-Alain Sahel, MD
Director of the Institut de la Vision (Sorbonne-Université/Inserm/CNRS), Paris; Chairman of the Department of Ophthalmology at Centre Hospitalier National d'Ophtalmologie des XV-XX, Paris; Professor and Chairman of the Department of Ophthalmology at University of Pittsburgh School of Medicine and UPMC (University of Pittsburgh Medical Center)

Robert C. Sergott, MD
Director, Neuro-Ophthalmology, Wills Eye Hospital and Director, William H. Annesley, Jr, EyeBrain Center, Thomas Jefferson University, Philadelphia, PA

Mark Moster, MD
Neuro-Ophthalmology, Wills Eye Hospital and Professor of Neurology and Ophthalmology at Thomas Jefferson University, Philadelphia, PA
(Investigator in REVERSE and RESCUE trials)

General Agenda

Date:
Thursday, May 23rd

Time:
8 am - Registration
8:30 am - 10:30 am - Presentation 

Location:
Parker New York
119 W 56th St
New York City

For more information or to RSVP, contact rjohn@troutgroup.com

RSVP for Event / Log Back in

Additional menu options can be found in the menu bar on the left or at the top.

GenSight Biologics [SIGHT:PA] €41 MM MCap
Gene ther­a­py: reti­nal & CNS de­gen­er­a­tive patholo­gies and mi­to­chon­drial dis­ease. Fil­ing for MAA exp Q4 2019 in EU and 2020 in US. Op­to­ge­net­ic pro­gram and tar­get­ed dis­ease im­me­di­ate­ly trans­fer­able to dry AMD. Plat­form com­bines mono-ge­net­ic ther­a­py-based ap­proach w core tech­nol­o­gy plat­form and pro­pri­e­tary Mi­to­chon­drial Tar­get­ing Se­quence. [more in­for­ma­tion]